Component
Short-term clinical endpoints in the LNAD trial
Context-specific entity; species, compartment and exposure are stated on each claim.
1 recorded relationships. Experimental role, claim status and evidence remain attached to each record.
How nutrients influence it
Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.
Other things that act on it
Enzymes, hormones, genes, and other components with a recorded effect. These are not nutrients, so they do not count toward the arrows above. Each finding names the chapter that recorded it.
How nutrients reach it in more than one step
Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.
Tracing routes…
What it does
Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.
What acts on it
No secondary clinical, vital-sign, wellbeing or wearable-derived endpoint survived multiplicity correction in the LNAD+ trial; one mild nausea event occurred in the active arm.
Experimental context and source evidence
- evidence_access
- Primary abstract
- experimental_model
- Same short trial; exploratory secondary outcomes.
- limitations
- Five days cannot establish long-term safety, longevity or disease prevention. Retrospective registration and industry-affiliated authors remain visible in the reference record.
- nutrient_topic
- NAD+ collection; molecular form, preparation, species, exposure and manipulation remain explicit. · NAD+
- plain_language
- A large biomarker change did not establish a clinical benefit.
- primary_references
- Oral LNAD+ rapidly elevates whole blood intracellular NAD and metabolic flux without elevating plasma NAD: evidence from a randomized controlled trial. · 2026 · https://pubmed.ncbi.nlm.nih.gov/42530810/ · DOI 10.1007/s11357-026-02399-1
NAD+: compartmental supply, consumption and cross-nutrient mechanisms (2026-09-19) · lines 324–330
AI-assisted research curation; primary references, access levels and experimental limitations individually identified. Not publisher full text. · supports · Same short trial; exploratory secondary outcomes. · source_derived_draft · unverified_draft
## nad-plus-oral-formulation-clinical-null A large biomarker change did not establish a clinical benefit. No secondary clinical, vital-sign, wellbeing or wearable-derived endpoint survived multiplicity correction in the LNAD+ trial; one mild nausea event occurred in the active arm. Model: Same short trial; exploratory secondary outcomes. Limitations: Five days cannot establish long-term safety, longevity or disease prevention. Retrospective registration and industry-affiliated authors remain visible in the reference record. Evidence access: Primary abstract Oral LNAD+ rapidly elevates whole blood intracellular NAD and metabolic flux without elevating plasma NAD: evidence from a randomized controlled trial. · 2026 · https://pubmed.ncbi.nlm.nih.gov/42530810/ · DOI 10.1007/s11357-026-02399-1
Complete structured claim and evidence
The events it takes part in
A mechanism often involves more than two components. These are the full events, with every participant and its role.
Situations it appears in
Low-supply and faulty-machinery situations recorded in the chapters where this component plays a part.
In the sources
Preserved passages that mention this component, quoted exactly. Open one to read it in context.
Open hypotheses
Proposed ideas that involve this component. They are labeled as hypotheses and do not change any recorded statement.
This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.